surmount-osa tirzepatide results Effect of treatment on patient-reported outcomes among SURMOUNT- OSA participants with obstructive sleep apnea and obesity SURMOUNT-5 (NCT05822830) top line results

All payments are cash-pay with no insurance coordination In-person visits are not offered

If you do not have insurance coverage, Semaglutide GLP-1 injections can be expensive

Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ

The fixed-effect sensitivity analysis preserved the overall directional ordering, supporting the robustness of the main interpretation (Supplementary Appendix 6)

It cited declining reimbursement rates, rising operational costs and a sustained decrease in patient utilization, and said no sustainable path forward could be found despite pursuing acquisitions and partnerships

Physiol 234, 1027010280